Saliva testing for multiple genes affecting cancer risk available

Docrates Cancer Center and GenoMill Health, a Finnish health technology company, bring a new Color gene risk test available for assessing hereditary risk of cancer. Identification of increased risk of cancer helps to plan monitoring for early detection of cancer.

Today, GenoMill Health and Docrates Cancer Center announced a new type of test that allows comprehensive, reliable and cost-effective screening for the most important hereditary factors in cancer. Color, a genetic test for inherited cancer risk, will become available through Docrates Cancer Center. It will contribute to comprehensive assessment of hereditary risk for breast and ovarian cancer and cancer of the large intestine, for example.

“Our test will make individual assessment of cancer risk commonly available,” says Marko Sirkiä, CEO of GenoMill Health. “A few years ago the BRCA gene test—the kind that, for example, Angelina Jolie tested positive for—costed thousands of euros. Technological development allows testing for 30 genes for one tenth of the former price.”

“We want to enable easy, fast and reliable access to important health information. We believe that everyone has a right to get information on their own risk factors, if they want to—without having to wait for months and having restricted access to the test.”

This test provides very significant information and requires genetic and medical know-how and support. Docrates Cancer Center makes this gene test available for everyone who is interested in their health in a responsible and professional way.

“When combined with visits to a specialist in medical genetics, the new test provides an important new service for people who have several cases of cancer in their family. The test is also suitable for patients with certain hereditary cancer,” says Tom Wiklund, Chief Clinical Director at Docrates Cancer Center. “Based on the test result and the patient’s background information, a specialist in medical genetics can assess the personal risk of the tested person and, together with other specialists, evaluate the need for monitoring for early detection or other actions. The test also helps to assess whether other family members should be tested.”

Recently, the Color test was selected for the Athena WISDOM study, which will involve 100,000 women, in the USA. That is one indicator of the credibility of the test features. The study aims to find new solutions for early detection of breast cancer.

Genetic testing practices are at a turning point. A recently published study found that a significant number of women are excluded from genetic testing because of restrictive criteria for testing (the so-called Lund criteria). According to a Norwegian study, more than half of risk mutation carriers remain unidentified if genetic testing is restricted on the basis of family history. The criteria have been useful because it has not been possible to offer expensive tests to a wider group. Development of the tests allows to loose the criteria for testing.

Additional information:

Tom Wiklund, Chief Clinical Director at Docrates Cancer Center,, +358 (0)50 500 1810.

 Marko Sirkiä, CEO of GenoMill Health,, +358 (0)40 554 6963.

Docrates Cancer Center is a Finnish-owned, international hospital in Helsinki specialising in cancer treatment. We provide services for cancer patients throughout the treatment chain, from diagnosis to post-treatment follow-up.  After the diagnosis and imaging, treatment can be planned and initiated without delay. Our unique concept attracts patients from all over the world. Together with our network of leading clinical experts, we provide state-of-the-art cancer therapies in line with our philosophy. So far, we have treated patients from over 50 countries and provided treatment for nearly 30 different types of cancer. We are experiencing strong international growth.

GenoMill is a Finnish health technology company that offers state-of-the-art solutions for genomics and diagnostics in the Nordic-Baltic region. The Color test is based on DNA sequencing technology. It analyses personal cancer risk based on family and personal health history and on the structure of 30 genes. The laboratory analysis is performed by Color Genomics in California,, www.syöpä